The use of immunotherapies in combination for the treatment of multiple myeloma

Heinz Ludwig, MD of the Wilhelminen Cancer Research Institute, Vienna, Austria and Niels van de Donk, MD, PhD, of the University Medical Center, Amsterdam hold a discussion on the novel checkpoint inhibitors used in multiple myeloma. Ludwig and van de Donk talk about the benefits of this class of drugs for high-risk patients and those with advance disease, and how they can be used in combination with other drugs, such as immunomodulatory drugs (IMIDs) and cell surface antigen targeting agents. However, van de Donk emphasizes the importance of waiting for data potentially being released in 2018 that can support the use of double or triple combinations, as at the moment physicians and researchers have only had the ability to hypothesize about this topic. The speakers in this video also discuss other immunotherapies, such as bi- and tri-specific antibodies that may be coupled with a toxin, and how they could help treat multiple myeloma. Niels van de Donk also mentions the importance of studying biomarkers to identify which patient will benefit from each treatment, and drugs used in other diseases such as PD-1 inhibitors.
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.

Share this video